[Request] Applied Genetic Technologies (AGTC)

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company’s advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials.

AGTC is a biotech company currently has two trials in the mid to late stages of trails for gene therapy of rare/debilitating dieses.